Last updated: July 10, 2026

Application No. 19/327,529

Untitled Application

Unknown

Filed

Priority

Feb 07, 2020 — provisional 62/971,906 +4 more

Examiner

ZAHORIK, AMANDA MARY

Art Unit

Tech Center

Intellia Therapeutics, Inc.

Assignee

Intellia Therapeutics Inc.

OA Round

1 (Non-Final)

This examiner grants 56% of cases after interview

— +47.8% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 69 resolved cases, 2023–2026

Examiner Intelligence

ZAHORIK, AMANDA MARY View full profile →

Grants 56% of resolved cases

Career Allowance Rate

39 granted / 69 resolved

-3.5% vs TC avg

Strong +48% interview lift

Without

With

+47.8%

Interview Lift

resolved cases with interview

Typical timeline

3y 6m

Avg Prosecution

41 currently pending

Career history

112

Total Applications

across all art units

Statute-Specific Performance

§101

0.4%

-39.6% vs TC avg

§103

47.6%

+7.6% vs TC avg

§102

8.9%

-31.1% vs TC avg

§112

25.2%

-14.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 69 resolved cases

Prosecution Timeline

Mar 30, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/312,721

Patent 12674166

RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF

5y 0m to grant Granted Jul 07, 2026

17/593,951

Patent 12674167

APTAMER SPECIFICALLY BINDING TO CANCER STEM CELLS, AND USE THEREOF

4y 9m to grant Granted Jul 07, 2026

17/598,627

Patent 12668795

INHIBITOR OF MIR-129 AND USES THEREOF

4y 9m to grant Granted Jun 30, 2026

18/269,089

Patent 12667629

INCREASED PACKAGING EFFICIENCY OF VECTOR FOR CARDIAC GENE THERAPY

3y 0m to grant Granted Jun 30, 2026

17/830,842

Patent 12662508

COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION

4y 0m to grant Granted Jun 23, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

56%

Grant Probability

99%

With Interview (+47.8%)

3y 6m

Median Time to Grant

Low

PTA Risk

Based on 69 resolved cases by this examiner. Grant probability derived from career allowance rate.